Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion

Infection and Immunity

Volumn 81, Issue 7, 2013, Pages 2507-2517

  Yao, Chaoqun ^a,b,c   Dixit, Upasna Gaur ^b   Barker, Jason H ^b   Teesch, Lynn M ^d   Love Homan, Laurie ^b   Donelson, John E ^d   Wilson, Mary E ^b,c,d  

^a UNIVERSITY OF WYOMING   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COMPLEMENT COMPONENT C3B; ERGOSTEROL; GLYCOSYLPHOSPHATIDYLINOSITOL; METHYL BETA CYCLODEXTRIN; PROTEINASE; STEROL; VIRULENCE FACTOR;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; COMPLEMENT SYSTEM; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFECTION RATE; LEISHMANIA CHAGASI; LEISHMANIA INFANTUM; LEISHMANIASIS; MACROPHAGE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NORMAL HUMAN; PARASITE LOAD; PARASITE VIABILITY; PARASITE VIRULENCE; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN CLEAVAGE; STEROL ANALYSIS;

ANIMALS; BETA-CYCLODEXTRINS; CELL MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT C3B; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MACROPHAGES; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; PARASITE LOAD; PARASITIC SENSITIVITY TESTS; PROTEIN BINDING; PROTEOLYSIS; PROTOZOAN PROTEINS; SERUM; STEROLS; VIRULENCE FACTORS;

EID: 84879443988     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00214-13     Document Type: Article

References (72)

1. Bates PA. 2007. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int. J. Parasitol. 37:1097-1106
2. Garcia LS. 2007. Diagnostic medical parasitology, 5th ed. ASM Press, Washington, DC
3. Desjeux P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27:305-318
4. Blackwell JM, Fakiola M, Ibrahim ME, Jamieson SE, Jeronimo SB, Miller EN, Mishra A, Mohamed HS, Peacock CS, Raju M, Sundar S, Wilson ME. 2009. Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol. 31:254-266
5. Beverley SM, Turco SJ. 1998. Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmania. Trends Microbiol. 6:35-40
6. Chang KP, McGwire BS. 2002. Molecular determinants and regulation of Leishmania virulence. Kinetoplastid Biol. Dis. 1:1
7. Yao C. 2010. Major surface protease of trypanosomatids: one size fits all? Infect. Immun. 78:22-31
8. Yao C, Donelson JE, Wilson ME. 2003. The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function. Mol. Biochem. Parasitol. 132:1-16
9. Denny PW, Field MC, Smith DF. 2001. GPI-anchored proteins and glycoconjugates segregate into lipid rafts in Kinetoplastida. FEBS Lett. 491:148-153
10. Denny PW, Goulding D, Ferguson MA, Smith DF. 2004. Sphingolipidfree Leishmania are defective in membrane trafficking, differentiation and infectivity. Mol. Microbiol. 52:313-327
11. Zufferey R, Allen S, Barron T, Sullivan DR, Denny PW, Almeida IC, Smith DF, Turco SJ, Ferguson MA, Beverley SM. 2003. Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J. Biol. Chem. 278:44708-44718
12. Brittingham A, Morrison CJ, McMaster WR, McGwire BS, Chang KP, Mosser DM. 1995. Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. J. Immunol. 155:3102-3111
13. Yao C, Leidal KG, Brittingham A, Tarr DE, Donelson JE, Wilson ME. 2002. Biosynthesis of the major surface protease GP63 of Leishmania chagasi. Mol. Biochem. Parasitol. 121:119-128
14. Yao C, Luo J, Hsiao C, Donelson JE, Wilson ME. 2005. Internal and surface subpopulations of the major surface protease (MSP) of Leishmania chagasi. Mol. Biochem. Parasitol. 139:173-183
15. Yao C, Luo J, Storlie P, Donelson JE, Wilson ME. 2004. Multiple products of the Leishmania chagasi major surface protease (MSP or GP63) gene family. Mol. Biochem. Parasitol. 135:171-183
16. Berens RL, Brun R, Krassner SM. 1976. A simple monophasic medium for axenic culture of hemoflagellates. J. Parasitol. 62:360-365
17. Spath GF, Beverley SM. 2001. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp. Parasitol. 99:97-103
18. Yao C, Chen Y, Sudan B, Donelson JE, Wilson ME. 2008. Leishmania chagasi: homogenous metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model. Exp. Parasitol. 118:129-133
19. Yao C, Donelson JE, Wilson ME. 2007. Internal and surface-localized MSP of Leishmania and their differential release from promastigotes. Eukaryot. Cell 6:1905-1912
20. Yao C, Li Y, Donelson JE, Wilson ME. 2010. Proteomic examination of Leishmania chagasi plasma membrane proteins: contrast between avirulent and virulent (metacyclic) parasite forms. Proteomics Clin. Appl. 4:4 -16
21. Wilson ME, Hardin KK, Donelson JE. 1989. Expression of the major surface glycoprotein of Leishmania donovani chagasi in virulent and attenuated promastigotes. J. Immunol. 143:678-684
22. Cauchetier E, Loiseau PM, Lehman J, Rivollet D, Fleury J, Astier A, Deniau M, Paul M. 2002. Characterisation of atovaquone resistance in Leishmania infantum promastigotes. Int. J. Parasitol. 32:1043-1051
23. Wilson ME, Andersen KA, Britigan BE. 1994. Response of Leishmania chagasi promastigotes to oxidant stress. Infect. Immun. 62:5133-5141
24. Chang HK, Thalhofer C, Duerkop BA, Mehling JS, Verma S, Gollob KJ, Almeida R, Wilson ME. 2007. Oxidant generation by single infected monocytes after short-term fluorescence labeling of a protozoan parasite. Infect. Immun. 75:1017-1024
25. Rodriguez NE, Gaur U, Wilson ME. 2006. Role of caveolae in Leishmania chagasi phagocytosis and intracellular survival in macrophages. Cell. Microbiol. 8:1106-1120
26. Stauber LA. 1958. Host resistance to the Khartoum strain of Leishmania donovani. Rice Inst. Pamphlets 45:80-90
27. Wilson ME, Innes DJ, Sousa AD, Pearson RD. 1987. Early histopathology of experimental infection with Leishmania donovani in hamsters. J. Parasitol. 73:55-63
28. Weirather JL, Jeronimo SM, Gautam S, Sundar S, Kang M, Kurtz MA, Haque R, Schriefer A, Talhari S, Carvalho EM, Donelson JE, Wilson ME. 2011. Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J. Clin. Microbiol. 49:3892-3904
29. Christian AE, Haynes MP, Phillips MC, Rothblat GH. 1997. Use of cyclodextrins for manipulating cellular cholesterol content. J. Lipid. Res. 38:2264-2272
30. Pucadyil TJ, Tewary P, Madhubala R, Chattopadhyay A. 2004. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol. Biochem. Parasitol. 133:145-152
31. Magaraci F, Jimenez CJ, Rodrigues C, Rodrigues JC, Braga MV, Yardley V, de Luca-Fradley K, Croft SL, de Souza W, Ruiz-Perez LM, Urbina J, Gonzalez Pacanowska D, Gilbert IH. 2003. Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J. Med. Chem. 46:4714-4727
32. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:352-357
33. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, Goad LJ. 2003. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126:129-142
34. Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R. 2002. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasitol. 125:35-45
35. Blackwell JM. 1985. Role of macrophage complement and lectin-like receptors in binding Leishmania parasites to host macrophages. Immunol. Lett. 11:227-232
36. Da Silva RP, Hall BF, Joiner KA, Sacks DL. 1989. CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J. Immunol. 143:617-622
37. Mosser DM, Edelson PJ. 1985. The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes. J. Immunol. 135:2785-2789
38. Ueno N, Bratt CL, Rodriguez NE, Wilson ME. 2009. Differences in human macrophage receptor usage, lysosomal fusion kinetics and survival between logarithmic and metacyclic Leishmania infantum chagasi promastigotes. Cell. Microbiol. 11:1827-1841
39. Puentes SM, Dwyer DM, Bates PA, Joiner KA. 1989. Binding and release of C3 from Leishmania donovani promastigotes during incubation in normal human serum. J. Immunol. 143:3743-3749
40. Ralton JE, Mullin KA, McConville MJ. 2002. Intracellular trafficking of glycosylphosphatidylinositol (GPI)-anchored proteins and free GPIs in Leishmania mexicana. Biochem. J. 363:365-375
41. Goluszko P, Nowicki B. 2005. Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cells. Infect. Immun. 73:7791-7796
42. Urbina JA. 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 114:91-99
43. Jacquier N, Schneiter R. 2012. Mechanisms of sterol uptake and transport in yeast. J. Steroid Biochem. Mol. Biol. 129:70-78
44. Sturley SL. 2000. Conservation of eukaryotic sterol homeostasis: new insights from studies in budding yeast. Biochim. Biophys. Acta 1529:155-163
45. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM. 2007. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 51:1425-1430
46. Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM. 2005. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob. Agents Chemother. 49:2677-2686
47. Torres-Santos EC, Sampaio-Santos MI, Buckner FS, Yokoyama K, Gelb M, Urbina JA, Rossi-Bergmann B. 2009. Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone. J. Antimicrob. Chemother. 63:469-472
48. Niedermeyer TH, Lindequist U, Mentel R, Gordes D, Schmidt E, Thurow K, Lalk M. 2005. Antiviral terpenoid constituents of Ganoderma pfeifferi. J. Nat. Prod. 68:1728-1731
49. Osumi T, Taketani S, Katsuki H, Kuhara T, Matsumoto I. 1978. Ergosterol biosynthesis in yeast. Pathways in the late stages and their variation under various conditions. J. Biochem. 83:681-691
50. Giner JL, Zhao H. 2004. Detailed sterol compositions of two pathogenic rust fungi. Lipids 39:763-767
51. Mosser DM, Brittingham A. 1997. Leishmania, macrophages and complement: a tale of subversion and exploitation. Parasitology 115:S9 -23
52. Chang CS, Chang KP. 1986. Monoclonal antibody affinity purification of a Leishmania membrane glycoprotein and its inhibition of leishmaniamacrophage binding. Proc. Natl. Acad. Sci. U. S. A. 83:100-104
53. Russell DG, Wilhelm H. 1986. The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages. J. Immunol. 136:2613-2620
54. Wilson ME, Hardin KK. 1988. The major concanavalin A-binding surface glycoprotein of Leishmania donovani chagasi promastigotes is involved in attachment to human macrophages. J. Immunol. 141:265-272
55. Ueno N, Wilson ME. 2012. Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival. Trends Parasitol. 28:335-344
56. Dahlin-Laborde RR, Yu TP, Beetham JK. 2005. Genetic complementation to identify DNA elements that influence complement resistance in Leishmania chagasi. J. Parasitol. 91:1058-1063
57. Franke ED, McGreevy PB, Katz SP, Sacks DL. 1985. Growth cycledependent generation of complement-resistant Leishmania promastigotes. J. Immunol. 134:2713-2718
58. Nunes AC, Almeida-Campos FR, Horta MF, Ramalho-Pinto FJ. 1997. Leishmania amazonensis promastigotes evade complement killing by interfering with the late steps of the cascade. Parasitology 115:601-609
59. Puentes SM, Sacks DL, da Silva RP, Joiner KA. 1988. Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J. Exp. Med. 167: 887-902
60. Silverman JM, Clos J, De'oliveira CC, Shirvani O, Fang Y, Wang C, Foster LJ, Reiner NE. 2010. An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. J. Cell Sci. 123:842-852
61. Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, Peters N, Adlem E, Tivey A, Aslett M, Kerhornou A, Ivens A, Fraser A, Rajandream MA, Carver T, Norbertczak H, Chillingworth T, Hance Z, Jagels K, Moule S, Ormond D, Rutter S, Squares R, Whitehead S, Rabbinowitsch E, Arrowsmith C, White B, Thurston S, Bringaud F, Baldauf SL, Faulconbridge A, Jeffares D, Depledge DP, Oyola SO, Hilley JD, Brito LO, Tosi LR, Barrell B, Cruz AK, Mottram JC, Smith DF, Berriman M. 2007. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 39:839-847
62. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schonian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M. 2011. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 21: 2143-2156
63. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, Sisk E, Rajandream MA, Adlem E, Aert R, Anupama A, Apostolou Z, Attipoe P, Bason N, Bauser C, Beck A, Beverley SM, Bianchettin G, Borzym K, Bothe G, Bruschi CV, Collins M, Cadag E, Ciarloni L, Clayton C, Coulson RM, Cronin A, Cruz AK, Davies RM, De Gaudenzi J, Dobson DE, Duesterhoeft A, Fazelina G, Fosker N, Frasch AC, Fraser A, Fuchs M, Gabel C, Goble A, Goffeau A, Harris D, Hertz-Fowler C, Hilbert H, Horn D, Huang Y, Klages S, Knights A, Kube M, Larke N, Litvin L, Lord A, et al. 2005. The genome of the kinetoplastid parasite, Leishmania major. Science 309:436-442
64. Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, Depledge DP, Harris D, Her Y, Herzyk P, Imamura H, Otto TD, Sanders M, Seeger K, Dujardin JC, Berriman M, Smith DF, Hertz-Fowler C, Mottram JC. 2011. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 21:2129-2142
65. Raymond F, Boisvert S, Roy G, Ritt JF, Legare D, Isnard A, Stanke M, Olivier M, Tremblay MJ, Papadopoulou B, Ouellette M, Corbeil J. 2012. Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res. 40:1131-1147
66. Gangneux J-P, Dullin M, Sulahian A, Garin YJ-F, Derouin F. 1999. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrob. Agents Chemother. 43:172-174
67. Haughan PA, Chance ML, Goad LJ. 1995. Effects of an azasterol inhibitor of sterol 24-transmethylation on sterol biosynthesis and growth of Leishmania donovani promastigotes. Biochem. J. 308:31-38
68. Lorente SO, Rodrigues JC, Jimenez Jimenez C, Joyce-Menekse M, Rodrigues C, Croft SL, Yardley V, de Luca-Fradley K, Ruiz-Perez LM, Urbina J, de Souza W, Gonzalez Pacanowska D, Gilbert IH. 2004. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother. 48:2937-2950
69. Ramos H, Saint-Pierre-Chazalet M, Bolard J, Cohen BE. 1994. Effect of ketoconazole on lethal action of amphotericin B on Leishmania mexicana promastigotes. Antimicrob. Agents Chemother. 38:1079-1084
70. Rodrigues JCF, Attias M, Rodriguez C, Urbina JA, Souza Wd. 2002. Ultrastructural and Biochemical Alterations Induced by 22,26-Azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob. Agents Chemother. 46:487-499
71. Saint-Pierre-Chazalet M, Ben Brahim M, Le Moyec L, Bories C, Rakotomanga M, Loiseau PM. 2009. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. J. Antimicrob. Chemother. 64:993-1001
72. Mishra BB, Kale RR, Singh RK, Tiwari VK. 2009. Alkaloids: future prospective to combat leishmaniasis. Fitoterapia 80:81-90.